Synonym
(+)-Leucinol, AI3-62983, Leucinol, L-Leucinol, L-(+)-Leucinol, (S)-(+)-Leucinol
IUPAC/Chemical Name
1-Pentanol, 2-amino-4-methyl-, (S)-
InChi Key
VPSSPAXIFBTOHY-LURJTMIESA-N
InChi Code
1S/C6H15NO/c1-5(2)3-6(7)4-8/h5-6,8H,3-4,7H2,1-2H3/t6-/m0/s1
SMILES Code
N[C@@H](CC(C)C)CO
Purity
>97% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
L-Leucinol ((+)-Leucinol) is a competitive aminopeptidase inhibitor with Ki value of 17 μM.
In vivo activity:
Targeting K-Leu using the leucine analogue leucinol can inhibit LARS activity, reverse TBX5 K-Leu modification, and decrease the occurrence of CHD in high-leucine-diet fed mice.
Reference: Adv Sci (Weinh). 2022 May;9(15):e2201034. https://pubmed.ncbi.nlm.nih.gov/35320615/
Preparing Stock Solutions
The following data is based on the
product
molecular weight
117.19
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Zhang X, Liu L, Chen WC, Wang F, Cheng YR, Liu YM, Lai YF, Zhang RJ, Qiao YN, Yuan YY, Lin Y, Xu W, Cao J, Gui YH, Zhao JY. Gestational Leucylation Suppresses Embryonic T-Box Transcription Factor 5 Signal and Causes Congenital Heart Disease. Adv Sci (Weinh). 2022 May;9(15):e2201034. doi: 10.1002/advs.202201034. Epub 2022 Mar 23. PMID: 35320615; PMCID: PMC9130917.
In vivo protocol:
1. Zhang X, Liu L, Chen WC, Wang F, Cheng YR, Liu YM, Lai YF, Zhang RJ, Qiao YN, Yuan YY, Lin Y, Xu W, Cao J, Gui YH, Zhao JY. Gestational Leucylation Suppresses Embryonic T-Box Transcription Factor 5 Signal and Causes Congenital Heart Disease. Adv Sci (Weinh). 2022 May;9(15):e2201034. doi: 10.1002/advs.202201034. Epub 2022 Mar 23. PMID: 35320615; PMCID: PMC9130917.
1: Yoon S, Kim JH, Yoon I, Kim C, Kim SE, Koh Y, Jeong SJ, Lee J, Kim S, Lee J. Discovery of (S)-4-isobutyloxazolidin-2-one as a novel leucyl-tRNA synthetase (LRS)-targeted mTORC1 inhibitor. Bioorg Med Chem Lett. 2016 Jul 1;26(13):3038-3041. doi: 10.1016/j.bmcl.2016.05.011. Epub 2016 May 7. PubMed PMID: 27209231.
2: Kabeshov MA, Kysilka O, Rulíšek L, Suleimanov YV, Bella M, Malkov AV, Kočovský P. Cross-Aldol Reaction of Isatin with Acetone Catalyzed by Leucinol: A Mechanistic Investigation. Chemistry. 2015 Aug 17;21(34):12026-33. doi: 10.1002/chem.201500536. Epub 2015 Jul 6. PubMed PMID: 26147182.
3: Ha JJ, Han HJ, Kim HE, Jin JS, Jeong ED, Hyun MH. Development of an improved ligand exchange chiral stationary phase based on leucinol for the resolution of proton pump inhibitors. J Pharm Biomed Anal. 2014 Nov;100:88-93. doi: 10.1016/j.jpba.2014.07.029. Epub 2014 Aug 2. PubMed PMID: 25137653.
